HopeStage
Back to all studies
CompletedNCT06342310

RE104 safety and efficacy for postpartum depression

About this titleRead the official source — NCT06342310

This study evaluated the safety and effectiveness of RE104 for Injection for people with depression.

Medication studyAges 18–45United States
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of RE104 for Injection for people with depression.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.

Listed locations
Birmingham and 37 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: June 14, 2024
Recruitment status
Completed
Enrollment listed in the registry
84
Sponsor
Reunion Neuroscience Inc
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 45 Years
Official registry ID
NCT06342310
Official title
Show the full official title

A Multicenter, Randomized, Double-Blind, Parallel-Group Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Patients With Postpartum Depression (PPD)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham · Tucson · Santa Monica

31 more locations
  • Boulder
  • Denver
  • Lauderhill
  • Tampa
  • Atlanta
  • Decatur
  • Marietta
  • Savannah
  • Honolulu
  • Kansas City
  • Shreveport
  • Baltimore
  • Rockville
  • Springfield
  • Novi
  • Albuquerque
  • Buffalo
  • New York
  • Chapel Hill
  • Monroe
  • Cleveland
  • Columbus
  • West Chester
  • Austin
  • Plano
  • San Antonio
  • Draper
  • Salt Lake City
  • Charlottesville
  • Seattle
  • Madison

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of RE104 for Injection for people with depression.

Who is behind this study?

The study sponsor is Reunion Neuroscience Inc.

Did this study involve medication?

Yes. The study involved medication, including RE104 for Injection.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies